(GSA) SSA/EA/Rig eval (Pharm S&S)

The Centers for Disease Control and Prevention is forecasting an opportunity to utilize enhanced evaluation methods to implement an effective pharmacist-led intervention aimed at improving hypertension control and expanding access to healthcare services. This initiative will leverage the expertise of pharmacists to deliver targeted clinical interventions, with a focus on measurable outcomes in blood pressure management and broader equity in healthcare delivery. The effort is classified under NAICS code 541720, indicating it pertains to scientific research and development services, and will require robust analytical frameworks to assess the intervention’s impact, scalability, and effectiveness across diverse populations. Although the solicitation number and specific contract details are not yet available, the forecast indicates that a program point of contact, Joanna Elmi, is available for inquiries, with the contracting officer position to be determined. The opportunity is open to potential vendors capable of designing, implementing, and evaluating evidence-based pharmaceutical care models in community or clinical settings. The anticipated performance location is unspecified, suggesting nationwide applicability, and the project will likely involve collaboration with healthcare providers, public health agencies, and patient communities to ensure sustainable and inclusive health outcomes. This forecast signals an upcoming formal procurement aimed at strengthening public health infrastructure through innovative pharmacy services.